Hyaluronidase

Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data showing 100% MRD negativity in newly diagnosed multiple myeloma patients treated with MajesTEC-5 induction and MajesTEC-4 maintenance therapies, presented at the 2024 ASH Annual Meeting.

Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data from MajesTEC-5 and MajesTEC-4 studies, showing 100% MRD negativity in evaluable patients with newly diagnosed multiple myeloma, presented at the 2024 ASH Annual Meeting.

DARZALEX FASPRO significantly delayed progression from high-risk SMM to active MM and extended overall survival in Phase 3 AQUILA study, presented at 2024 ASH Annual Meeting.

DARZALEX FASPRO® significantly delayed progression from high-risk SMM to active MM and extended overall survival in the Phase 3 AQUILA study, compared to active monitoring.

The CEPHEUS trial showed that adding daratumumab to VRd significantly improved MRD negativity and complete response rates in transplant-ineligible NDMM patients. The quadruplet regimen achieved a 60.9% MRD negativity rate vs. 39.4% with VRd alone, with superior sustained MRD negativity and progression-free survival. These results support the use of daratumumab in frontline treatment for this patient population.

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO and DARZALEX SC for high-risk smoldering multiple myeloma, supported by Phase 3 AQUILA study data, aiming to shift treatment paradigm.

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO as monotherapy for high-risk smoldering multiple myeloma, supported by Phase 3 AQUILA study data. The first AQUILA study results will be presented at the 2024 ASH Annual Meeting.

Johnson & Johnson seeks FDA and EMA approval for subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in high-risk smoldering multiple myeloma, supported by the AQUILA study. Initial AQUILA findings to be presented at the 2024 ASH Annual Meeting.